CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
像 ABC 一样简单：管理抗体-药物偶联物、双特异性抗体和 CAR-T 细胞治疗的毒性
英文原题：Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies.
查看英文原题
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
抗体偶联药物（ADC）、T细胞衔接型双特异性抗体（BsAb）及嵌合抗原受体（CAR）T细胞，已成为广泛使用的标准疗法，改变了淋巴系统和浆细胞恶性肿瘤的治疗。随着近期监管批准，这些疗法也有望改变常见实体瘤的治疗，并成为肿瘤科医生日常诊疗中的“ABC”。本文借鉴血液肿瘤领域经验，回顾ADC、BsAb和CAR-T 细胞的早期、晚期及罕见毒性，并提供其管理的一般原则。
展开英文摘要原文
Antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric antigen receptor (CAR) T cells are widely used standard-of-care therapies that have revolutionized the treatment of lymphoid and plasma cell malignancies.
With recent regulatory approvals, these therapies are poised to also revolutionize the treatment of common solid tumors and become a part of the everyday lexicon, the ABCs, of the practicing oncologist. Drawing from experience in hematology, we review the early, late, and rare toxicities of ADCs, BsAbs, and CAR T cells and provide general principles for their management.
论文信息
- 作者
- Jain MD、Abramson JS、Ansell SM
- 第一作者单位
- Moffitt Cancer Center, Tampa, FL.United States
- 通讯作者单位
- Mayo Clinic, Rochester, MN.United States
- 文献类型
- 综述
- 期刊
- American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2025 Jun
- 原文标识
- PubMed 40294348 · DOI 10.1200/EDBK-25-473916